Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsBOM:533573 +0.31%75 Gross Margin % is 71.20% as of Mar. 2026, which is 6% above its 10-year median of 67.28. GuruFocus rates BOM:533573 with a GF Score™ of 75/100 and a GF Value™ of ₹1,054.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 941 Drug Manufacturers companies, Alembic Pharmaceuticals ranks better than 85.76% on this metric.
BOM:533573's Gross Margin % is ranked better than 85.76% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:533573: 72.98
Alembic Pharmaceuticals had a gross margin of 71.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Alembic Pharmaceuticals was -0.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alembic Pharmaceuticals had a gross margin of 71.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Alembic Pharmaceuticals Gross Margin % Related Terms
Alembic Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533573 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alembic Pharmaceuticals (BOM:533573) has a Gross Margin % of 71.20% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Alembic Pharmaceuticals and its competitors. This is near median its historical median of 67.28. Over the past decade, Alembic Pharmaceuticals' Gross Margin % has ranged from 63.21 to 72.98. According to the industry distribution chart, Alembic Pharmaceuticals ranks #134 out of 941 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Alembic Pharmaceuticals' Gross Margin % too high?
Alembic Pharmaceuticals' current Gross Margin % of 71.20% is near median its 10-year median of 67.28. Over the past 10 years, this metric has ranged from a low of 63.21 to a high of 72.98. The Drug Manufacturers industry median Gross Margin % is 48.54. Alembic Pharmaceuticals' value of 71.20% is 46.7% above this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #134 out of 941 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alembic Pharmaceuticals has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #134 out of 941 companies for Gross Margin %. This places Alembic Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Alembic Pharmaceuticals' value of 71.20% is 46.7% above this benchmark. Historically, Alembic Pharmaceuticals' own Gross Margin % has ranged from 63.21 to 72.98 over the past decade. While the company's 10-year median is 67.28 vs. the industry median of 48.54, Alembic Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current Gross Margin % of 71.20% is 46.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current Gross Margin % is 71.20%, which is near median its own 10-year median of 67.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,054.49, compared to a current price of ₹796.50 — trading 24.5% below its estimated fair value. The current Gross Margin % is 71.20%, which is near median its 10-year median of 67.28 and 46.7% above the Drug Manufacturers industry median of 48.54. Alembic Pharmaceuticals' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current Gross Margin % is 71.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹796.50 is trading 24.5% below its estimated GF Value™ of ₹1,054.49.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:533573:
Gross Margin %: 71.20% (near median its 10-year median of 67.28)
GF Value™: ₹1,054.49 vs. price of ₹796.50 (24.5% below fair value)
Industry Position: 46.7% above the Drug Manufacturers median (#134 of 941)
No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
75GF Score
Get the complete analysis for BOM:533573
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533573 has been successfully added to your 
